Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

This combination has been evaluated in patients with endometrial cancer and renal cell carcinoma, results of which were presented at the 2017 ASCO Annual Meeting and the 2017 EMSO Congress, respectively. Results in both trials demonstrated promising response rates and progression-free survival, Zamarin says.

The rationale for combining these drugs is not completely clear, says Zamarin, but these trials prove how little is known about the potential of drugs not initially developed to target the immune system.